The Cellular Senescence and Pathophysiology Group, Cardiff Metropolitan University, Cardiff, United Kingdom.
Fundación Para La Investigación Biomédica Del Hospital Universitario De Getafe, Getafe, Spain.
Gerontology. 2021;67(2):202-210. doi: 10.1159/000512287. Epub 2021 Jan 21.
The evidence that blood levels of the soluble receptor for advanced glycation end products (sRAGE) predict mortality in people with cardiovascular diseases (CVD) is inconsistent. To clarify this matter, we investigated if frailty status influences this association.
We analysed data of 1,016 individuals (median age, 75 years) from 3 population-based European cohorts, enrolled in the FRAILOMIC project. Participants were stratified by history of CVD and frailty status. Mortality was recorded during 8 years of follow-up.
In adjusted Cox regression models, baseline serum sRAGE was positively associated with an increased risk of mortality in participants with CVD (HR 1.64, 95% CI 1.09-2.49, p = 0.019) but not in non-CVD. Within the CVD group, the risk of death was markedly enhanced in the frail subgroup (CVD-F, HR 1.97, 95% CI 1.18-3.29, p = 0.009), compared to the non-frail subgroup (CVD-NF, HR 1.50, 95% CI 0.71-3.15, p = 0.287). Kaplan-Meier analysis showed that the median survival time of CVD-F with high sRAGE (>1,554 pg/mL) was 2.9 years shorter than that of CVD-F with low sRAGE, whereas no survival difference was seen for CVD-NF. Area under the ROC curve analysis demonstrated that for CVD-F, addition of sRAGE to the prediction model increased its prognostic value.
Frailty status influences the relationship between sRAGE and mortality in older adults with CVD. sRAGE could be used as a prognostic marker of mortality for these individuals, particularly if they are also frail.
可溶性晚期糖基化终产物受体（sRAGE）血水平预测心血管疾病（CVD）患者死亡率的证据并不一致。为了澄清这一点，我们研究了虚弱状态是否会影响这种关联。
我们分析了来自 3 个基于人群的欧洲队列的 1016 名（中位年龄 75 岁）参与者的 FRAILOMIC 项目数据。参与者根据 CVD 病史和虚弱状态进行分层。在 8 年的随访期间记录死亡率。
在调整后的 Cox 回归模型中，基线血清 sRAGE 与 CVD 患者死亡率升高相关（HR 1.64，95%CI 1.09-2.49，p=0.019），但与非 CVD 患者无关。在 CVD 组中，与非虚弱亚组（CVD-NF，HR 1.50，95%CI 0.71-3.15，p=0.287）相比，虚弱亚组（CVD-F，HR 1.97，95%CI 1.18-3.29，p=0.009）的死亡风险明显增加。Kaplan-Meier 分析显示，sRAGE 水平较高（>1554pg/mL）的 CVD-F 的中位生存时间比 sRAGE 水平较低的 CVD-F 短 2.9 年，而 CVD-NF 则没有生存差异。ROC 曲线下面积分析表明，对于 CVD-F，sRAGE 的加入增加了预测模型的预后价值。
虚弱状态影响 sRAGE 与老年 CVD 患者死亡率之间的关系。sRAGE 可作为这些患者死亡率的预后标志物，特别是如果他们也虚弱的话。
